Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 8/20 | 0.47 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.40 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17065792 | 0.85 | NR4A2 (0.44) | NR4A2MTNR1AMTNR1BCREBBPNPC1 | |
| SCHEMBL703667 | 0.80 | NR4A2 (0.52) | NR4A2MTNR1AMTNR1BCREBBPMAPT | |
| SCHEMBL21419429 | 0.77 | NR4A2 (0.55) | NR4A2SERPINH1CREBBP | |
| SCHEMBL7264993 | 0.76 | ALDH1A1 (0.44) | SERPINH1MAPTTHRBPTGDRPTGDR2 | |
| SCHEMBL14466455 | 0.74 | ABL1 (0.50) | NR4A2MAPTTHRBPTGDRPTGDR2 | |
| SCHEMBL27531827 | 0.72 | GPR17 (0.42) | NR4A2GPR17MTNR1AMTNR1BMAPT | |
| SCHEMBL17065789 | 0.71 | KDM4E (0.35) | SERPINH1MAPTTHRBPTGDRPTGDR2 | |
| SCHEMBL5187070 | 0.70 | KDM4E (0.38) | NPC1MAPTTHRB | |
| SCHEMBL21367013 | 0.70 | KDM4E (0.36) | NR4A2CREBBPNPC1MAPT | |
| SCHEMBL16401877 | 0.69 | GAA (0.42) | SERPINH1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170015666-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015666-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| EP-3114125-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015132765-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015132765-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015666-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | NR4A2 722/4885GPR17 4115/4885SERPINH1 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.